Metastatic Paraganglioma

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2023 Jan 18

PMID 36653043

Authors

Daniela Harmsworth

Andrew Mallia

James DeGaetano

Paul John Cassar

Affiliations

Soon will be listed here.

Abstract

A man in his 70s, with a history of a glomus jugulare paraganglioma diagnosed 18 years ago, presented with an unprovoked deep vein thrombosis (DVT). The paraganglioma had been treated by radiotherapy, and yearly scans had not shown any progression since treatment. A sclerotic focus in L4 vertebral body was reported on a CT scan of the neck and trunk which was done to exclude a neoplastic process being the precipitating factor for the DVT. Nuclear imaging showed multiple areas of bony uptake, suggestive of metastases. A bone biopsy of the left femur resulted positive for metastatic paraganglioma. A monthly intramuscular injection of octreotide 30 mg was prescribed.

References

Dahia P, Clifton-Bligh R, Gimenez-Roqueplo A, Robledo M, Jimenez C . HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop. Endocr Relat Cancer. 2020; 27(8):T41-T52. PMC: 7334096. DOI: 10.1530/ERC-19-0435. View

Boedeker C, Neumann H, Maier W, Bausch B, Schipper J, Ridder G . Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg. 2007; 137(1):126-9. DOI: 10.1016/j.otohns.2007.01.015. View

Tenenbaum F, Schlumberger M, Lumbroso J, Parmentier C . Beneficial effects of octreotide in a patient with a metastatic paraganglioma. Eur J Cancer. 1996; 32A(4):737. DOI: 10.1016/0959-8049(95)00617-6. View

Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg S . Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008; 113(8):2020-8. PMC: 9094399. DOI: 10.1002/cncr.23812. View

Martins R, Bugalho M . Paragangliomas/Pheochromocytomas: clinically oriented genetic testing. Int J Endocrinol. 2014; 2014:794187. PMC: 4037125. DOI: 10.1155/2014/794187. View

Welander J, Soderkvist P, Gimm O . Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011; 18(6):R253-76. DOI: 10.1530/ERC-11-0170. View

Mete O, Asa S, Gill A, Kimura N, de Krijger R, Tischler A . Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022; 33(1):90-114. DOI: 10.1007/s12022-022-09704-6. View

Torres-Costa M, Flores B, Torregrosa N, Gonzalez M, Rios A, Febrero B . Malignant prediction in paragangliomas: analysis for clinical risk factors. Langenbecks Arch Surg. 2021; 406(7):2441-2448. DOI: 10.1007/s00423-021-02222-9. View

Chen H, Sippel R, ODorisio M, Vinik A, Lloyd R, Pacak K . The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010; 39(6):775-83. PMC: 3419007. DOI: 10.1097/MPA.0b013e3181ebb4f0. View

10.

Al-Harthy M, Al-Harthy S, Al-Otieschan A, Velagapudi S, Alzahrani A . Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas. Endocr Pract. 2009; 15(3):194-202. DOI: 10.4158/EP.15.3.194. View

11.

Korevaar T, Grossman A . Pheochromocytomas and paragangliomas: assessment of malignant potential. Endocrine. 2011; 40(3):354-65. DOI: 10.1007/s12020-011-9545-3. View

12.

Jha A, Patel M, Baker E, Gonzales M, Ling A, Millo C . Role of Ga-DOTATATE PET/CT in a Case of -Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide. Nucl Med Mol Imaging. 2020; 54(1):48-52. PMC: 7062954. DOI: 10.1007/s13139-019-00629-3. View

13.

Harari A, Inabnet 3rd W . Malignant pheochromocytoma: a review. Am J Surg. 2010; 201(5):700-8. DOI: 10.1016/j.amjsurg.2010.04.012. View

14.

Young W . Metastatic Pheochromocytoma: In Search of a Cure. Endocrinology. 2020; 161(3). DOI: 10.1210/endocr/bqz019. View

15.

Ilanchezhian M, Jha A, Pacak K, Del Rivero J . Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. Curr Treat Options Oncol. 2020; 21(11):85. PMC: 7456409. DOI: 10.1007/s11864-020-00787-z. View

16.

Manolidis S, Shohet J, Jackson C, GLASSCOCK 3rd M . Malignant glomus tumors. Laryngoscope. 1999; 109(1):30-4. DOI: 10.1097/00005537-199901000-00007. View

17.

Gimenez-Roqueplo A, Dahia P, Robledo M . An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res. 2012; 44(5):328-33. DOI: 10.1055/s-0031-1301302. View

18.

Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J . Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007; 92(10):3822-8. DOI: 10.1210/jc.2007-0709. View

19.

Fishbein L, Merrill S, Fraker D, Cohen D, Nathanson K . Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol. 2013; 20(5):1444-50. PMC: 4291281. DOI: 10.1245/s10434-013-2942-5. View

20.

Fliedner S, Lehnert H, Pacak K . Metastatic paraganglioma. Semin Oncol. 2010; 37(6):627-37. PMC: 3018803. DOI: 10.1053/j.seminoncol.2010.10.017. View